ITQB

[Frontier Leaders] Understanding complex glycan utilization in the human microbiota: Harry John Gilbert, Institute for Cell and Molecular Biosciences, University of Newcastle Upon Time, UK
Located in Events / Seminars
[Frontier Leaders] X-ray spectroscopic studies of biological dinitrogen reduction in the Molybdenum and Vanadium Nitrogenases: Serena DeBeer, Max Planck Institute for Chemical Energy Conversion, Germany
Located in Events / Seminars
[iBET - ITQB NOVA] Biopharmaceutical Process Development and Manufacturing: Industry Experience and Perspective from an ITQB alumnus: Nuno Fontes, Executive Director of Process Science, Boehringer-Ingelheim, Fremont, California, USA
Located in Events / Seminars
[iBET – iNOVA4Health Seminar] Addressing unmet medical need: Key drivers for Drug Discovery at Bayer: Andreas Busch, Head of Drug Discovery – Bayer Pharmaceuticals
Located in Events / Seminars
[iBET – ITQB NOVA Seminar] Developability Assessment of therapeutic Antibodies: Thorsten Lorenz, Novartis Pharma AG, Basel, Switzerland
Located in Events / Seminars
[iBET – ITQB NOVA] Small molecule modulation of lipid metabolism protect β cells against Lipotoxic induced dysfunction: Located in Events / Seminars
[iBET – ITQB Seminar] Humans-on-a-chip – a paradigm shift in substance testing?!: Uwe Marx, CEO, TissUse GmbH
Located in Events / Seminars
[iBET – ITQB Seminar] Innovation in Biologics Manufacturing: Hitto Kaufmann, Technology and Development Sanofi Biologics, Germany
Located in Events / Seminars
[iBET – ITQB Seminar] microRNAs as biomarker of drug-induced tissue injury: Philippe Couttet, Novartis Institutes of Biomedical Research in Basel, Switzerland
Located in Events / Seminars
[iBET – ITQB Seminar] Vectors carrying heterologous RNA for designing new viral vaccines: Carlos Augusto Pereira, Instituto Butantan, Laboratorio de Imunologia Viral, São Paulo, Brazil
Located in Events / Seminars

« Previous 10 items Next 10 items » 1 ... 26 27 28 [29] 30 31 32 ... 433

Personal tools

Search results for à